Attend

ASTCT + EBMT 6TH INTERNATIONAL CONFERENCE ON RELAPSE AFTER TRANSPLANT AND CELLULAR THERAPY (HSCT²)

Leadership

ASTCT and EBMT are proud to present the ASTCT/EBMT 6th International Conference on Relapse After Transplant and Cellular Therapy (HSCT²) taking place on November 10 - 11 in Los Angeles, California.

Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies treated with both allogeneic and autologous hematopoietic stem cell transplantation. During the last 5 years significant advances have been made in our understanding of the biology of relapse such as understanding the role of HLA loss in leukemia recurrence post-transplant. Since our 1st relapse meeting we now have three drugs approved to prevent disease recurrence post autologous transplant, and the role of FLT3 inhibitors and other TKIs to prevent relapse post allogeneic HCT is actively ongoing. Finally, the efficacy of CD 19 CAR T cell therapy for patients with disease relapsing after HCT has been firmly established for ALL and NHL.

Registration

Register

Registration Type	Price
Standard Registration (MD, PhD)	$500
Trainees and Junior Faculty	$350
Allied Health Professionals	$350
Industry*	$850

The Standard, Trainees, and Allied Health Professional registration rates are reserved for individuals currently practicing in the field of transplantation and cellular therapy field.

*If your company is interested in participating as a sponsor, please contact Angie Dahl.

Meeting Venue

Sheraton Universal Hotel
333 Universal Hollywood Drive
Universal City, CA 91608
(818) 980-1212

Room Rate
$279.00 plus 16.19% tax per night (single/double). The room rate will increase by $20 per night for additional persons.

Housing Rate Cutoff
To take advantage of the discounted room rate, be sure to book your reservation on or before October 18, 2023. After October 18, the room block will be released and the negotiated room rates may not be available. Please make sure the hotel is aware of any special needs. They will assign specific room types and any other requests based on availability.

Deposits
Please have your credit card information on hand upon booking your reservation. The Sheraton Universal Hotel requires each individual reservation be guaranteed with a deposit equal to one night's room and tax.

Changes or Cancellations
The Sheraton Universal Hotel requires that you cancel your reservation (72) hours prior to your arrival. The deposit of one night's room and tax will be forfeited for cancellations made less than (72) hours from arrival. Please call the hotel directly to make a cancellation and keep your cancellation confirmation number for your records. Name changes can be made to reservations any time prior to check-in, without incurring a fee.

Confirmations
The hotel will send you a confirmation to the email used in booking your reservation using the customized online reservation link provided by ASTCT-EBMT. Review it carefully for accuracy and keep a copy for your records.

Near by thing to do
There are lots of attractions located near the Sheraton Universal Hotel. Visit their website to discover, fitness, swimming, golf, and family friendly activities.

Agenda*

Day 1: Friday, November 10

Time	Session
8:00 - 8:05 a.m.	Welcome and Introduction Alan Wayne, MD; Children's Hospital Los Angeles/University of Southern California Michael Bishop, MD; University of Chicago Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center Nicolaus Kroger, MD; University Hospital Hamburg
8:05 - 8:15 a.m.	Message from the ASTCT and EBMT President's Miguel Perales, MD; Memorial Sloan Kettering Cancer Center Anna Sureda, MD; Institut Català d'Oncologia-Hospital Duran i Reynals
8:15 - 9:00 a.m.	Keynote: Immunometabolic control of immunity and the effects of fever Jeffrey C. Rathmell, PhD; Vanderbilt University
9:00 - 10:30 a.m.	Session I.A: Immune Reconstitution Session Chairs: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center; Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center Title: NK-like T cells: broad immunity and potential for cell therapy Speaker: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center Title: Harnessing mechanisms of tissue regeneration to boost T cell reconstitution after HCT Speaker: Jarrod Dudakov, PhD; Fred Hutchinson Cancer Center Session I.B: Microbiome Session Chairs: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center; Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center Title: Microbiome, HCT, and Immunotherapy Speaker: Jonathan Peled, MD, PhD; Memorial Sloan Kettering Cancer Center Title: Microbial metabolites rescue antibiotic-associated neutropenia Speaker: Katherine King, MD, PhD; Baylor College of Medicine
10:30 - 11:00 a.m.	Break
11:00 - 11:45 a.m.	Session II: Mechanism of Relapse – Allo Session Chairs: Leslie Kean, MD, PhD; Dana-Farber Cancer Institute/Boston’s Children Hospital; Luca Vago, MD, PhD; San Raffaele Scientific Institute Title: Leukemia Immune Escape and Relapse after Allogeneic HCT: From Biology to Personalized Medicine (And Back) Speaker: Luca Vago, MD, PhD; San Raffaele Scientific Institute Title: Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to limit relapse after HSCT Speaker: Simone Minnie, PhD; Fred Hutchinson Cancer Center
11:45 - 1:00 p.m. 12:00 - 12:45 p.m.	Lunch Pfizer Product Theater
1:00 - 1:45 p.m.	Session III: Mechanism of Relapse – Auto Session Chairs: Anna Sureda, MD; Institut Català d'Oncologia-Hospital Duran i Reynals; Marcos de Lima, MD; Ohio State University Title: Mechanisms of relapse after ASCT in multiple myeloma Speaker: Niccolo Bolli, MD, PhD; Universita degli Studi di Milano Statale Title: Lymphoma recurrence after autologous stem cell transplantation Speaker: Lapo Alinari, MD, PhD; Ohio State University
1:45 - 2:15 p.m.	Break
2:15 - 3:30 p.m.	Session IV: Mechanism of Relapse – CAR Resistance Session Chairs: Nirali Shah, MD, MHSc, National Cancer Institute; Michael Bishop, MD; University of Chicago Title: Determinants of resistance to anti-CD19 CAR T-cells in large B-cell lymphoma Speaker: Brian Sworder, MD, PhD; Stanford Health Care Title: Harnessing CAR/TCR cross-talk to enhance immunotherapeutic precision Speaker: Naomi Taylor, MD, PhD; National Cancer Institute Title: ALL relapse prevention with HCT following CD19 CAR T cell remission Speaker: Corrine Summers, MD; Seattle Children's Hospital/Fred Hutchinson Cancer Center
3:30 - 4:15 p.m.	Keynote Lecture: Towards the Development of Synthetic Immunity to Cancer Kole Roybal, PhD; University of California, San Francisco
4:15 - 5:15 p.m.	Best Oral Abstracts Abstract Title: Guided Lymphocyte Immunopeptide Derived Expansion(GLIDE) and Infusion, a Phase I clinical trial of anti-minor histocompatibility antigen expanded T cells to target leukemia relapsing after HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation Abstract Presenter: Sylvie Lachance MD, FRCPC; Hôpital Maisonneuve-Rosemont Abstract Title: Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33,shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk AML and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) post-hematopoietic cell transplant (HCT) maintenance Abstract Presenter: Guenther Koehne, MD, PhD; Miami Cancer Institute Abstract Title: Immune reconstitution in human bone marrow demonstrates unique features that may correlate with leukemia relapse risk post-transplant Abstract Presenter: Susan Ehrenkranz De Wolf, MD; Memorial Sloan Kettering Cancer Center Abstract Title: Mutation clearance of driver mutations after transplantation for myelofibrosis predicts outcome Abstract Presenter: Nico Gagelmann, MD; University Medical Center Hamburg-Eppendorf
5:15 - 6:45 p.m.	Welcome Reception

Day 2: Saturday, November 11

Time	Session
7:00 - 8:00 a.m.	Product Theater
8:00 - 8:45 a.m.	Keynote Lecture: Missing the Major Correlate of Risk of Posttransplant Relapse John DiPersio, MD, PhD; Washington University, St. Louis
8:45 - 9:30 a.m.	Session V: Mechanism of Relapse - Focus on T Cells Session Chairs: Robert Zeiser, MD; University of Freiburg; Shannon McCurdy, MD; University of Pennsylvania Title: How to improve the anti-tumor activity of T cells – metabolism gives some answers Speaker: Petya Apostolova, MD; University of Basel, Switzerland Title: Lessons from azithromycin after alloHSCT: how an antibiotic can promote relapse by disrupting immune and metabolic networks Speaker: David Michonneau, MD, PhD; Hopital Saint-Louis
9:30 - 10:00 a.m.	Break
10:00 - 11:15 a.m.	Session VI: Minimal Residual Disease Session Chairs: Charles Craddock, MD; University Hospitals of Birmingham; Brenda Sandmaier, MD; Fred Hutchinson Cancer Center Title: MRD and Relapse after Transplant in Patients with AML Speaker: Sylvie Freeman, DPhil, MBChB, MRCP, FRCPath, University of Birmingham Title: Using MRD to Predict and Prevent Relapse after HCT and CAR Therapy Speaker: Michael Pulsipher, MD; University of Utah Title: Assessment, considerations and management of Multiple myeloma patients following front line autologous stem cell transplantation Speaker: Graham Jackson, MD; Newcastle University
11:15 - 12:30 p.m.	Session VII: Relapse Prevention Session Chair: David Porter, MD; University of Pennsylvania Title: Non-targeted strategies for relapse prevention Speaker: Victoria Potter, BSc, MBBS; Kings Private Hospital Title: FLT3 inhibitors as maintenance therapy after HCT Speaker: Alexander Perl, MD; University of Pennsylvania Title: Inhibition of MDM2 for relapse prevention Speaker: Nana Talvard-Balland, PhD; University of Freiburg
12:30 - 1:45 p.m. 12:45 - 1:15 p.m.	Lunch California Institute for Regenerative Medicine
1:45 - 3:15 p.m.	Session VIII: Treatment of Relapse Session Chairs: Rayne Rouce, MD; Texas Children’s Hospital/Baylor College of Medicine; Saar Gill, MD, PhD; University of Pennsylvania; Bronwen Shaw, MD, PhD; CIBMTR/Medical College of Wisconsin; Takanori Teshima, MD, PhD; Hokkaido University Title: Treatment of Relapse Post Allogeneic Stem Cell Transplantation: A Overview Speaker: Saar Gill, MD, PhD; University of Pennsylvania Title: How I treat AML relapse post allogeneic stem cell transplantation Speaker: Leonido Luznik, MD; Johns Hopkins Medicine Title: Treatment of Relapsed Myeloid Disease Post Allogeneic HCT: HMA, Venetoclax and DLI Speaker: Hugo Fernandez, MD; Moffit Cancer Center Title: 4 How I treat ALL relapse post allogeneic stem cell transplantation(including Ph+ and Ph-, and T-ALL) Speaker: Rayne Rouce, MD; Texas Children's Hospital/Baylor College of Medicine
3:15 - 3:30 p.m.	Concluding Remarks

*This agenda is current as of September 2023 but is subject to change.

Accreditation

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professions Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

Sponsorship

Please contact Angie Dahl for opportunities to sponsor or exhibit at the ASTCT/EBMT 6th International Conference on Relapse After Transplant and Cellular Therapy (HSCT²).

Questions?

For any questions related to registration, housing, accreditation, or other conference questions, please contact the ASTCT Headquarters.